MedTrace Logo

Efficacy of Uremic Toxins Clearance With Expanded Hemodialysis

NCT04786535 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-09-17

No results posted yet for this study

Summary

The aim of this study is to quantify the B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx (expanded hemodialysis), HDc (high-flux conventional hemodialysis), or HDF (hemodiafiltration).

And to compare the magnitude of the B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF

Conditions

Interventions

PROCEDURE

Expanded Hemodialysis

* Single-use Theranova 400 Dialyzer * Blood flow (Qb) minimum of 300 mL/min * Dialysis flow (Qd) 500 mL/min * Minimum therapy time of 4 hours * Ultrafiltration necessary to achieve dry weight

PROCEDURE

High-flux Conventional Hemodialysis

* Single-use high-flux hemodialyzer * Blood flow (Qb) minimum of 300 mL/min * Dialysis flow (Qd) 500 mL/min * Minimum therapy time of 4 hours * Ultrafiltration necessary to achieve dry weight

PROCEDURE

Hemodiafiltration

* Single-use high-flux hemodialyzer * Post-dilution mode * Minimum convective volume of 23 L * Blood flow (Qb) minimum of 300 mL/min * Dialysis flow (Qd) 700 mL/min * Minimum therapy time of 4 hours * Ultrafiltration necessary to achieve dry weight

Sponsors & Collaborators

  • Baxter México

    collaborator UNKNOWN

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    lead OTHER

Principal Investigators

  • Ricardo Correa-Rotter, MD · Head Departament of Nephrology and Mineral Metabolism,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2021-09-06
Completion
2022-01-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04786535 on ClinicalTrials.gov